Universal Infectious Disease Screening and Management in Pregnancy

Screening Recommendations

All pregnant individuals should receive universal screening for hepatitis B surface antigen, hepatitis C antibodies, HIV, and syphilis at the first prenatal visit, irrespective of vaccination history or perceived risk. [1][2]
Hepatitis B screening is mandated for every pregnant individual at the initial visit even if they have been previously vaccinated or tested negative in earlier pregnancies. [3][4]5
Universal hepatitis C antibody screening is recommended for every pregnancy. [1][2]
Pregnant patients identified as hepatitis C‑positive should also be screened for HIV, syphilis, gonorrhea, chlamydia, and hepatitis B if these tests have not already been performed. [1][2]
When intra‑hepatic cholestasis of pregnancy is diagnosed early or when bile‑acid levels are markedly elevated, clinicians should add viral hepatitis screening. [1][2]
A complete blood count should be obtained at the first visit to identify anemia. 6
Routine ABO and RhD typing should be performed at the first prenatal encounter. 6
Proteinuria assessment should be included in the initial work‑up to evaluate pre‑eclampsia risk. 6

Vaccination Recommendations

The inactivated influenza vaccine should be administered to all pregnant individuals during any trimester. [7][8]9
Tdap (tetanus, diphtheria, acellular pertussis) vaccination is advised during each pregnancy. [7][8]
Hepatitis A and hepatitis B vaccines are indicated for hepatitis C‑positive pregnant patients who lack immunity. [1][2]
Live attenuated vaccines—including LAIV, MMR, varicella, yellow fever, and live bacterial vaccines—are contraindicated throughout pregnancy. [7][8]
Any recommended vaccines that could not be administered during pregnancy should be given immediately postpartum. [7][8]9

Hepatitis C Management

Routine antenatal testing solely for hepatitis C diagnosis is not required; however, a third‑trimester ultrasound may be considered to monitor fetal growth when maternal infection is present. [1][2]
Direct‑acting antiviral therapy should be limited to clinical‑trial settings during pregnancy; patients who become pregnant while on treatment require counseling regarding potential risks and benefits. [1][2]
Internal fetal monitoring devices and early artificial rupture of membranes should be avoided unless clinically essential (e.g., inability to obtain an external fetal heart‑rate trace). [1][2]
Cesarean delivery should not be performed solely because of maternal hepatitis C infection. [1][2]
Breastfeeding is not contraindicated for hepatitis C‑positive mothers unless there is nipple cracking or bleeding. [1][2]

Hepatitis B Newborn Prophylaxis

Infants born to mothers who test positive for hepatitis B surface antigen must receive hepatitis B vaccine and hepatitis B immune globulin within 12 hours of birth. 5
If maternal hepatitis B status is unknown at delivery, the newborn should receive hepatitis B vaccine within 12 hours; hepatitis B immune globulin should be administered within 7 days if the mother later tests positive. 5
Accurate and timely transfer of maternal hepatitis B results to labor/delivery teams and newborn records is essential to ensure appropriate prophylaxis. [4][10]5

System Coordination and Follow‑up

Universal infectious‑disease screening applies to all pregnant individuals, with no exemptions for low‑risk populations, regardless of prior vaccination or perceived risk. [1][2]
Health‑care systems should establish protocols that guarantee reliable transmission of screening results to delivery providers, facilitating correct newborn prophylaxis. [4][10]5
Household contacts of hepatitis C‑positive pregnant patients should be offered appropriate immunizations to reduce secondary exposure risk. [1][2]

Initial Prenatal Laboratory Screening Recommendations

Mandatory Infectious Disease Screening

The American College of Obstetricians and Gynecologists (ACOG) recommends universal syphilis screening at the first prenatal visit using a nontreponemal test (RPR or VDRL), with confirmatory treponemal testing if the result is positive. 11
ACOG advises that all pregnant women be screened for hepatitis B surface antigen (HBsAg) at the initial prenatal visit, irrespective of prior vaccination or documented immunity. 12
ACOG endorses universal HIV antibody testing for every pregnant woman at the first prenatal visit. 13

Timing and Follow‑up Recommendations

All recommended laboratory tests (syphilis, hepatitis B, HIV, CBC, blood type/Rh, rubella immunity) should be obtained during the first prenatal visit, preferably in the first trimester, to permit early diagnosis and management. 13
For women identified as high‑risk for syphilis (e.g., uninsured, living in poverty, sex workers, illicit drug users, or residing in high‑prevalence communities), ACOG recommends repeat syphilis screening in the third trimester (≈ 28 weeks) and again at delivery. 11
When follow‑up testing for a positive syphilis result is required, the same nontreponemal assay (RPR or VDRL) used initially should be employed to ensure comparable titers over time. 11

Implementation Considerations

Clinicians should not omit syphilis screening even in low‑risk populations, as universal screening is mandated by state regulations and endorsed by major professional societies. 14
Prior hepatitis B vaccination status must not be used to forgo HBsAg testing; every pregnant patient requires this screening. 12
Prompt transmission of hepatitis B screening results to labor and delivery teams is essential to arrange appropriate newborn prophylaxis (e.g., hepatitis B immunoglobulin and vaccine). 12

Initial Antenatal Laboratory Testing Guidelines

Universal Infectious Disease Screening

All pregnant individuals should have hepatitis B surface antigen (HBsAg) testing at the first prenatal visit, regardless of prior vaccination or previous negative results, to identify maternal infection and enable timely newborn prophylaxis (hepatitis B vaccine ± HBIG within 12 h). 15
HIV antibody testing must be performed for every pregnant patient at the initial visit to detect maternal infection and allow early antiretroviral therapy. 16
Syphilis screening should be done universally using a nontreponemal assay (RPR or VDRL) with confirmatory treponemal testing if positive, to prevent congenital syphilis. 17
Rubella immunity status should be assessed at the first prenatal visit to determine need for postpartum vaccination. 17
When varicella immunity is uncertain, varicella‑specific antibody testing should be performed to guide vaccination decisions. 17

Baseline Laboratory Assessments

A complete blood count (CBC) should be obtained at the initial visit to detect anemia, which is associated with increased risk of preterm delivery, intra‑uterine growth restriction, and perinatal depression. 15
ABO blood type and Rh(D) typing are required for all pregnant patients to identify Rh‑negative individuals who will need Rh immune‑globulin to prevent alloimmunization. 15

Targeted Metabolic and Substance‑Use Screening

Women with risk factors (e.g., body‑mass index > 25 kg/m²) should undergo diabetes screening at the first prenatal visit using standard diagnostic criteria, because obesity is linked to gestational diabetes, hypertension, miscarriage, and stillbirth. 18
All pregnant patients should be screened for substance use at the first visit with a validated instrument such as the NIDA Quick Screen Tool, enabling early intervention and referral. 19

Implementation and Timing

All recommended laboratory tests should be completed during the first prenatal visit, preferably in the first trimester, to allow early diagnosis and management that improves maternal‑fetal outcomes. 15
No risk‑based exemptions are permitted; prior vaccination or perceived low‑risk status must not be used to omit hepatitis B screening. 15